Personalized Cholestatic Disease Management System

A comprehensive system for personalized treatment of cholestatic diseases, integrating biomarkers, tailored therapy selection, and real-time monitoring to improve treatment outcomes and patient quality of life.

The original patent relates to methods of treatment of cholestatic diseases, specifically PBC and/or PSC. However, these treatments often have inadequate response rates, and there is a need for more effective and personalized approaches. The new inventive concept addresses this limitation by providing a system that takes into account individual patient profiles, biomarkers, and treatment response data to deliver optimized treatment regimens.

The system comprises a biomarker panel for identifying a patient's specific disease profile, a tailored therapy selection module for determining an optimal treatment regimen based on the patient's profile, and a device for non-invasive, real-time monitoring of bile flow and composition. The system may also include a computer-implemented method for identifying novel therapeutic targets, a personalized nutrition and lifestyle planning system, and a method for predicting treatment outcomes. These components work together to provide a comprehensive and adaptive approach to managing cholestatic diseases.

The new inventive concept introduces a paradigm shift in cholestatic disease treatment by integrating multiple components to deliver personalized medicine. The use of biomarkers, tailored therapy selection, and real-time monitoring is a novel combination that goes beyond the original patent's methods. The inventive step lies in the system's ability to adapt to individual patient needs and provide optimized treatment regimens.

Alternative embodiments of the system may include variations in the biomarker panel, therapy selection algorithms, or monitoring devices. For example, the system could incorporate additional biomarkers, such as genetic or epigenetic markers, or utilize machine learning algorithms to predict treatment outcomes. Other variations may include different types of monitoring devices, such as implantable sensors or mobile apps.

The personalized cholestatic disease management system has significant commercial potential in the healthcare industry, particularly in the areas of precision medicine and digital health. The system could be marketed to pharmaceutical companies, healthcare providers, and patients with cholestatic diseases, offering a new standard of care and improved treatment outcomes.